CA2168012A1 - Polymeric matrices and their uses in pharmaceutical compositions - Google Patents

Polymeric matrices and their uses in pharmaceutical compositions

Info

Publication number
CA2168012A1
CA2168012A1 CA002168012A CA2168012A CA2168012A1 CA 2168012 A1 CA2168012 A1 CA 2168012A1 CA 002168012 A CA002168012 A CA 002168012A CA 2168012 A CA2168012 A CA 2168012A CA 2168012 A1 CA2168012 A1 CA 2168012A1
Authority
CA
Canada
Prior art keywords
pharmaceutical compositions
polymeric matrices
ethylenecarbonate
tnf
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002168012A
Other languages
French (fr)
Other versions
CA2168012C (en
Inventor
Murat Acemoglu
Siegfried Bantle
David Bodmer
Salvatore Cammisuli
Peter Hiestand
Fritz Nimmerfall
Georg Stoll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939317822A external-priority patent/GB9317822D0/en
Priority claimed from GB939320240A external-priority patent/GB9320240D0/en
Priority claimed from GB939325900A external-priority patent/GB9325900D0/en
Priority claimed from GB9407156A external-priority patent/GB9407156D0/en
Application filed by Individual filed Critical Individual
Priority to CA002474988A priority Critical patent/CA2474988C/en
Publication of CA2168012A1 publication Critical patent/CA2168012A1/en
Application granted granted Critical
Publication of CA2168012C publication Critical patent/CA2168012C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/18—Block or graft polymers
    • C08G64/183—Block or graft polymers containing polyether sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/02—Aliphatic polycarbonates
    • C08G64/0208—Aliphatic polycarbonates saturated
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
    • C08G64/20—General preparatory processes
    • C08G64/32—General preparatory processes using carbon dioxide
    • C08G64/34—General preparatory processes using carbon dioxide and cyclic ethers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylenecarbonate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF.alpha., e.g., certain autoimmune and inflammatory conditions, as well as septic shock.
CA002168012A 1993-08-27 1994-08-26 Polymeric matrices and their uses in pharmaceutical compositions Expired - Lifetime CA2168012C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002474988A CA2474988C (en) 1993-08-27 1994-08-26 Polymeric matrices and their uses in pharmaceutical compositions

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB9317822.6 1993-08-27
GB939317822A GB9317822D0 (en) 1993-08-27 1993-08-27 Organic compounds
GB939320240A GB9320240D0 (en) 1993-10-01 1993-10-01 Improvements in or relating to organic compounds
GB9320240.6 1993-10-01
GB9325900.0 1993-12-17
GB939325900A GB9325900D0 (en) 1993-12-17 1993-12-17 Organic compounds
GB9407156A GB9407156D0 (en) 1994-04-11 1994-04-11 Organic compounds
GB9407156.0 1994-04-11
PCT/EP1994/002833 WO1995006077A2 (en) 1993-08-27 1994-08-26 Polymeric matrices and their uses in pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002474988A Division CA2474988C (en) 1993-08-27 1994-08-26 Polymeric matrices and their uses in pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CA2168012A1 true CA2168012A1 (en) 1995-03-02
CA2168012C CA2168012C (en) 2005-08-09

Family

ID=27451062

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002168012A Expired - Lifetime CA2168012C (en) 1993-08-27 1994-08-26 Polymeric matrices and their uses in pharmaceutical compositions

Country Status (24)

Country Link
US (2) US6083521A (en)
EP (2) EP1028137A3 (en)
JP (2) JP3343124B2 (en)
KR (1) KR100341995B1 (en)
CN (3) CN1326568C (en)
AT (1) ATE327273T1 (en)
AU (1) AU697995B2 (en)
BR (1) BR9407370A (en)
CA (1) CA2168012C (en)
CZ (1) CZ55296A3 (en)
DE (1) DE69434743T2 (en)
DK (1) DK0719295T3 (en)
ES (1) ES2262135T3 (en)
FI (1) FI960892A (en)
HU (1) HU220637B1 (en)
IL (1) IL110787A0 (en)
NO (2) NO960721L (en)
NZ (1) NZ273319A (en)
PL (1) PL182569B1 (en)
PT (1) PT719295E (en)
SG (2) SG87847A1 (en)
SK (1) SK25496A3 (en)
TW (1) TW492863B (en)
WO (1) WO1995006077A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2736550B1 (en) * 1995-07-14 1998-07-24 Sandoz Sa PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLID DISPERSION COMPRISING A MACROLIDE AND A VEHICLE
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6756060B1 (en) 1996-09-19 2004-06-29 Usbiomaterials Corp. Anti-inflammatory and antimicrobial uses for bioactive glass compositions
GB9725480D0 (en) * 1997-12-01 1998-01-28 Univ London Cytokines and their use in the treatment of established chronic infections and cancers
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US6100372A (en) * 1998-08-20 2000-08-08 Akzo Nobel Nv Monocarboxylic acid-terminated polymers of carbon dioxide and an alkylene oxide
EP1185247A4 (en) * 1999-04-29 2008-09-17 Usbiomaterials Corp Anti-inflammatory bioactive glass particulates
DK1196150T3 (en) 1999-06-14 2005-11-21 Imp College Innovations Ltd Solvent-containing sol-gel-derived bioglass compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
AU2001283304B2 (en) * 2000-08-11 2005-05-05 Favrille, Inc. Method and composition for altering a T cell mediated pathology
AU2001288829A1 (en) * 2000-09-06 2002-03-22 Ap Pharma, Inc. Degradable polyacetal polymers
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
JP2005516586A (en) * 2001-07-20 2005-06-09 ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ Reagents and methods for identifying gene targets for the treatment of cancer
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
CA2476556A1 (en) 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US8303625B2 (en) * 2002-04-18 2012-11-06 Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh Biodegradable shape memory polymeric sutures
CN100567987C (en) * 2002-08-08 2009-12-09 贝勒医学院 T cell vaccine and preparation method thereof
EP1558282A4 (en) * 2002-10-01 2006-04-19 Chiron Corp Anti-cancer and anti-infectious disease compositions and methods for using same
GB0228571D0 (en) * 2002-12-06 2003-01-15 Novartis Ag Organic compounds
WO2005063319A1 (en) * 2003-12-24 2005-07-14 Novartis Ag Parmaceutical compositions
AU2005240082B2 (en) * 2004-04-30 2009-07-23 Innatus Corporation Method and system to remove soluble TNFR1,TNFR2, and IL2 in patients
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
WO2006100844A1 (en) * 2005-03-18 2006-09-28 Mitsui Chemicals, Inc. Water environment sensitive polymer having biodegradability, process for production thereof, and water-degradable material
US20070099867A1 (en) * 2005-05-24 2007-05-03 Glycoscience Laboratories, Inc. Pharmaceutical agent containing hyaluronan as an active ingredient
SI1787658T1 (en) 2005-11-10 2012-07-31 Chemi Spa Sustained release formulations of somatostatin analogue inhibitors of growth hormone
PL2420833T3 (en) * 2006-05-05 2016-03-31 Opexa Therapeutics T-cell vaccine
JP5419699B2 (en) * 2006-10-31 2014-02-19 エボニック コーポレイション Spheroidized polymer particles
ES2718612T3 (en) 2007-12-20 2019-07-03 Evonik Corp Procedure for preparing microparticles that have a low volume of residual solvent
CN111848940A (en) 2008-09-08 2020-10-30 沙特阿美技术公司 Polycarbonate polyol compositions and methods
AU2009336723B2 (en) * 2008-12-15 2013-06-06 Novartis Ag Nanoparticle compositions
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
ES2749324T3 (en) * 2011-07-25 2020-03-19 Saudi Aramco Tech Co Polymeric compositions and methods
TR201202779A2 (en) 2012-03-12 2013-10-21 Petkim Petrokimya Holding Anonim Sirketi Polyethylene carbonate production method
EP2664641B1 (en) 2012-05-18 2018-04-25 Petkim Petrokimya Holding Anonim Sirekti Method for producing polyethylene carbonate with metal salts
KR102159100B1 (en) * 2012-05-24 2020-09-23 사우디 아람코 테크놀로지스 컴퍼니 Polycarbonate polyol compositions and methods
EP3584267A1 (en) 2012-11-07 2019-12-25 Saudi Aramco Technologies Company High strength polyurethane foam compositions and methods
WO2016144635A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation
AU2016291708B2 (en) 2015-07-13 2020-12-24 Beyondspring Pharmaceuticals, Inc Plinabulin compositions
IL260933B2 (en) 2016-02-08 2023-04-01 Beyondspring Pharmaceuticals Inc Plinabulin compositions
EP3463337A4 (en) 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
WO2018144764A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
CN112135614A (en) * 2018-01-24 2020-12-25 大连万春布林医药有限公司 Compositions and methods for reducing thrombocytopenia by administering plinabulin
WO2020028606A1 (en) 2018-08-02 2020-02-06 Saudi Aramco Technologies Company Sustainable polymer compositions and methods

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3585168A (en) * 1968-09-21 1971-06-15 Shohei Inoue Process for producing copolymer of epoxide and carbon dioxide
US3706713A (en) * 1970-08-11 1972-12-19 Shell Oil Co Aliphatic polycarbonates
JPS5341117B2 (en) * 1971-12-21 1978-10-31
US3953383A (en) * 1972-07-21 1976-04-27 Nippon Oil Seal Industry Co., Ltd. Catalytic process for copolymerizing epoxy compounds with carbon dioxide
JPS553288B2 (en) * 1973-08-06 1980-01-24
JPS5761769B2 (en) * 1974-03-20 1982-12-25 Nippon Oil Seal Ind Co Ltd
JPS5922731B2 (en) * 1975-09-12 1984-05-29 エヌオーケー株式会社 Method for producing copolymerization catalyst
JPS5438397A (en) * 1977-08-31 1979-03-22 Hidetoshi Tsuchida Copolymerization catalyst consisting of carbon dioxide and oxirane compoud
US4379138A (en) * 1981-12-28 1983-04-05 Research Triangle Institute Biodegradable polymers of lactones
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
JPH0725688B2 (en) * 1986-03-31 1995-03-22 住友製薬株式会社 CSF sustained release formulation
US4665136A (en) * 1986-04-07 1987-05-12 Air Products And Chemicals, Inc. Process for producing novel block alkylene polycarbonate copolymers
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JPH0725689B2 (en) * 1986-10-07 1995-03-22 中外製薬株式会社 Sustained-release preparation containing granulocyte colony-stimulating factor
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4783445A (en) * 1987-12-14 1988-11-08 Arco Chemical Company Soluble epoxide/carbon dioxide copolymerization catalysts
EP0390860B1 (en) * 1987-12-17 1995-04-12 United States Surgical Corporation Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US5274074A (en) * 1987-12-17 1993-12-28 United States Surgical Corporation Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US4789727A (en) * 1987-12-18 1988-12-06 Arco Chemical Company Reduction of catalyst usage in epoxide/CO2 polymerization
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
EP0358326B1 (en) * 1988-08-09 1996-12-27 Mitsui Petrochemical Industries, Ltd. Process for preparing a zinc-containing solid catalyst and process for preparing polyalkylene carbonate
ATE147634T1 (en) * 1988-12-19 1997-02-15 American Cyanamid Co PRODUCTS FOR TREATING ENDOTOXIN SHOCK IN A MAMMAL
WO1990009798A1 (en) * 1989-02-24 1990-09-07 Immunotherapeutics, Inc. Immobilized cytokines
US4999417A (en) * 1989-03-30 1991-03-12 Nova Pharmaceutical Corporation Biodegradable polymer compositions
US4960862A (en) * 1989-03-31 1990-10-02 Air Products And Chemicals, Inc. Regeneration of metallo-organic catalyst for carbon dioxide-epoxide copolymerization
US5026676A (en) * 1989-06-07 1991-06-25 Air Products And Chemicals, Inc. Catalyst for the copolymerization of epoxides with CO2
US4943677A (en) * 1989-06-08 1990-07-24 Air Products And Chemicals, Inc. Making poly(alkylene carbonates) of controlled molecular weight
JP2693584B2 (en) * 1989-06-26 1997-12-24 三井石油化学工業株式会社 Method for producing catalyst component for producing polyalkylene carbonate
US5126147A (en) * 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
JP2930362B2 (en) * 1990-04-09 1999-08-03 東ソー株式会社 A therapeutic agent for a sensitized T cell-related disease
DE69008526T2 (en) * 1990-07-02 1994-08-18 Bend Res Inc Asymmetric microporous beads for adjustable release.
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
ATE155154T1 (en) * 1990-11-13 1997-07-15 Isi Ist Sierovaccinogeno Ital FUNCTIONAL POLYESTERS MADE OF GLYCIDYL DERIVATIVES AND CYCLIC ANHYDRIDES OR CARBON DIOXIDE
CA2099376A1 (en) * 1991-01-03 1992-07-04 Henry E. Auer Stabilization of proteins by cationic biopolymers
CA2060635A1 (en) * 1991-02-12 1992-08-13 Keith D'alessio Bioabsorbable medical implants
IT1248061B (en) * 1991-06-14 1995-01-05 Mediolanum Farmaceutici Spa POLYCARBONATES AND THEIR USE FOR THE PREPARATION OF BIOERODIBLE MATRICES
US5344644A (en) * 1991-08-01 1994-09-06 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release
CA2079509C (en) * 1991-10-01 2002-05-14 Shigeyuki Takada Prolonged release microparticle preparation and production of the same
AU3244693A (en) * 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
JPH05194253A (en) * 1992-01-16 1993-08-03 Kirin Brewery Co Ltd Sustained release particulate pharmaceutical containing water-soluble polypeptide hormone and its production
GB9206736D0 (en) * 1992-03-27 1992-05-13 Sandoz Ltd Improvements of organic compounds and their use in pharmaceutical compositions
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
GB9406094D0 (en) * 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
JP3028227B1 (en) 1998-12-15 2000-04-04 穎助 藤本 Disposal needleless syringe

Also Published As

Publication number Publication date
EP0719295B1 (en) 2006-05-24
ATE327273T1 (en) 2006-06-15
JP2003002844A (en) 2003-01-08
TW492863B (en) 2002-07-01
AU7655794A (en) 1995-03-21
CN1506116A (en) 2004-06-23
US6083521A (en) 2000-07-04
CA2168012C (en) 2005-08-09
CN1129947A (en) 1996-08-28
SG87847A1 (en) 2002-04-16
KR100341995B1 (en) 2002-11-23
BR9407370A (en) 1996-07-16
SG50724A1 (en) 1999-10-19
WO1995006077A3 (en) 1995-05-04
DE69434743T2 (en) 2006-11-16
AU697995B2 (en) 1998-10-22
CN1344755A (en) 2002-04-17
FI960892A (en) 1996-04-18
PL312717A1 (en) 1996-05-13
NO960721L (en) 1996-04-26
DK0719295T3 (en) 2006-09-25
CN1085687C (en) 2002-05-29
JP4477813B2 (en) 2010-06-09
NZ273319A (en) 1998-02-26
WO1995006077A2 (en) 1995-03-02
ES2262135T3 (en) 2006-11-16
DE69434743D1 (en) 2006-06-29
PL182569B1 (en) 2002-01-31
JPH09501967A (en) 1997-02-25
NO960721D0 (en) 1996-02-23
US6262127B1 (en) 2001-07-17
NO20021141L (en) 1996-04-26
EP1028137A2 (en) 2000-08-16
CZ55296A3 (en) 1996-09-11
HU9600456D0 (en) 1996-04-29
PT719295E (en) 2006-10-31
HUT74568A (en) 1997-01-28
JP3343124B2 (en) 2002-11-11
HU220637B1 (en) 2002-03-28
EP0719295A1 (en) 1996-07-03
FI960892A0 (en) 1996-02-26
CN1258551C (en) 2006-06-07
EP1028137A3 (en) 2000-11-02
SK25496A3 (en) 1997-03-05
IL110787A0 (en) 1994-11-11
NO20021141D0 (en) 2002-03-07
CN1326568C (en) 2007-07-18

Similar Documents

Publication Publication Date Title
CA2168012A1 (en) Polymeric matrices and their uses in pharmaceutical compositions
CA2348016A1 (en) Controlled release liquid delivery compositions with low initial drug burst
MY107500A (en) Preparation process of sustained release compositions and the compositions thus obtained
HUP0102385A2 (en) Liquid polymeric compositions for controlled release of bioactive substances
CA2106079A1 (en) Pegylation of polypeptides
ZA987087B (en) Chemical compounds
CA2041774A1 (en) Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
AU2748392A (en) Low molecular weight poly(alkylene) and hydrogenated poly(vinyl aromatic/conjugated diene) block copolymer containing compositions and their novel applications
GR3036586T3 (en) Novel hydrogels containing triblock copolymers, and preparation and use thereof
ES2167784T3 (en) RETICULATED COPOLYMERS BASED ON POLYCARBOXYL POLYMERS.
ES2094359T3 (en) PHARMACEUTICAL FORMULATIONS OF OSTEOGENIC PROTEINS.
ES2145013T3 (en) BLOOD COAGULATION FORMULATIONS - OSTEOGENIC PROTEIN POLYMER MATRIX.
CA2075358A1 (en) Multimers of the soluble forms of tnf receptors, their preparation and pharmaceutical compositions containing them
IL136054A0 (en) Poly(vinylamine) -based superabsorbent gels and method of manufacturing the same
MX9705763A (en) Oil gel formulations containing high vinyl content hydrogenated styrene-butadiene-styrene block copolymers.
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
AU5588100A (en) Compositions comprising hydrogenated block copolymers and end-use applications thereof
AU5148800A (en) Compositions comprising hydrogenated block copolymers and end-use applications thereof
CA2171446A1 (en) Pseudo- and non-peptide bradykinin receptor antagonists
CA2336149A1 (en) A membrane or matrix for controlling the permeation rate of drugs
EP2289499A3 (en) Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
CA2474988A1 (en) Polymeric matrices and their uses in pharmaceutical compositions
HK1029099A1 (en) 2-amino-6-methyl-7-acetyl-tetraline and pharmaceutical compositions for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
MX9805045A (en) Polymeric fluorescence quenching compounds and their use.
ATE415150T1 (en) SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING A CEPHALOSPORIN ANTIBIOTIC

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140826